GSK plc reported that on June 1, 2024, a Delaware State Court ruling contradicts a previous Federal Court decision regarding Zantac (ranitidine) litigation, allowing claims to proceed despite scientific evidence showing no cancer risk. GSK will appeal the ruling and maintain its capital allocation plans unaffected by this legal issue.